Compare AbbVie Inc (ABBV) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? AbbVie Inc trades at $253.74 (market cap $449.91B), while C.H. Robinson Worldwide, Inc. trades at $189.55 (market cap $22.49B). The key difference: AbbVie Inc is far larger — about 20× C.H. Robinson Worldwide, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CHRW | |
|---|---|---|
Market Cap | $449.91B | $22.49B |
Sector | Health | Industrials |
52-Week High | $261.07 | $200.59 |
52-Week Low | $184.85 | $96.82 |
Enterprise Value | $513.38B | $23.98B |
Dividend Yield | 2.72% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
CH Robinson Worldwide (CHRW) trades at $190.95, up 0.58% with a bullish technical outlook. The stock shows strong profitability with ROE of 34.84% and has beaten earnings estimates for three consecutive quarters. Recent acquisitions like DeSpir Logistics and AI technology launches position the company for growth in logistics efficiency. Valuation metrics appear elevated with P/E of 38.18, though revenue has declined from 2022 peaks to $16.23B in 2025.
The outlook remains positive with analyst consensus target of $198.83 representing 4% upside. Key opportunities include AI-driven supply chain optimization and industry consolidation benefits, while risks involve freight market volatility and competitive pressures. Cash flow generation remains healthy with $915M operating cash flow in 2025 supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
